Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hal Barron
Biotech
LifeMine locks down $70M 'dream scenario' fungi deal with GSK
LifeMine and GSK have had a relationship for at least two years, and now they're making it official with a $70 million drug discovery pact.
Annalee Armstrong
Mar 23, 2022 6:30am
GSK kills one of Barron's early darlings, axing Epizyme pact
Feb 9, 2022 6:14am
Altos exits stealth with $3B, dream team C-suite and big vision
Jan 19, 2022 7:50am
Barron quits GSK to take CEO post at $3B biotech startup
Jan 19, 2022 7:30am
New GlaxoSmithKline keeping old R&D model, says embattled CEO
Jul 29, 2021 7:17am
GSK sees 'modest' impact on trials, preps for 'busy few months'
Apr 30, 2020 7:30am
